The relationship between serum insulin-like growth factor-2 levels and clinical characteristics in patients with schizophrenia
10.3969/j.issn.1002-0152.2015.07.004
- VernacularTitle:精神分裂症血清胰岛素样生长因子2与临床特征的关系
- Author:
Feng LIANG
;
Yuanjian YANG
;
Jianwen XIONG
;
Haibo CHEN
;
Jinqiong ZHAN
;
Dan LIAO
;
Chaoxiong ZHOU
;
Maorong HU
;
Kun YAN
;
Bo WEI
- Publication Type:Journal Article
- Keywords:
Schizophrenia;
Insulin-like growth factor-2 (IGF-2);
Negative symptoms;
Cognitive function
- From:
Chinese Journal of Nervous and Mental Diseases
2015;(7):401-405,430
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the change of serum insulin-like growth factor-2 (IGF-2) and its relationship with clinical characteristics in patients with schizophrenia. Methods Fifty-one schizophrenic patients were recruited in the present study and 50 healthy volunteers served as controls. The serum IGF-2 level was measured using enzyme linked immunosorbent assay (ELISA). Positive and Negative Syndrome Scale (PANSS) was used to evaluate the psychotic symp?toms of patients. Trail Making Test-A (TMTA), Digit-Symbol Coding Test (DSCT), Continuous Performance Test (CPT) and Stroop Color-Word Test (SCWT) were used to evaluate the cognitive function of both groups. Results There were sig?nificant differences in the results of TMTA, DSCT, CPT and SCWT between patient and control groups. The serum levels of IGF-2 were significantly lower in patients than that in controls [(202.7±40.7) ng/mL vs. (365.9±65.5) ng/mL, P<0.01]. The levels of serum IGF-2 were not significantly different between first-episode and recurrent schizophrenic patients (P>0.05). Furthermore, significant correlations were found between the serum IGF-2 level and the negative symptom sub?scale of PANSS (r=-0.397, P=0.004), CPT score (r=0.378, P=0.006), SCWT-word number (r=0.289, P=0.040), SC? WT-color number (r=0.327, P=0.019) and SCWT-word/color number (r=0.386, P=0.005) in schizophrenic patients. Con?clusion The serum IGF-2 levels of patients with schizophrenia are significantly lower than that of healthy controls, and the IGF-2 level is associated with the severity of negative symptoms and cognitive impairments in patients, indicating that serum IGF-2 might be an indicator of the severity of schizophrenia.
